Legal and regulatory barriers to developing evidence and communicating findings on treatments in real-world settings are interfering with the sharing of knowledge among providers, patients, and researchers.

That’s the message to federal lawmakers from Mary Grealy, president of the Healthcare Leadership Council which represents CEOs of healthcare organizations, during testimony on July 22 before the House Energy and Commerce Subcommittee on Health. Though opportunities exist to capture and analyze data in real-world delivery settings, they are being hindered. What is needed, say advocates, is the free flow of data, research, and results related to the benefits and risk profiles of drugs and devices to advance the discovery, development and delivery cycles.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access